# Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

> **NCT01278160** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 179 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30
- **DRUG:** biphasic insulin aspart 30
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT01278160
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01278160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01278160, "Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01278160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*